214 related articles for article (PubMed ID: 23377402)
1. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
Azzouni F; Zeitouni N; Mohler J
J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402
[TBL] [Abstract][Full Text] [Related]
2. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
3. Androgens in women: Hormone-modulating therapies for skin disease.
Azarchi S; Bienenfeld A; Lo Sicco K; Marchbein S; Shapiro J; Nagler AR
J Am Acad Dermatol; 2019 Jun; 80(6):1509-1521. PubMed ID: 30312645
[TBL] [Abstract][Full Text] [Related]
4. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders.
Chen W; Zouboulis CC; Orfanos CE
Dermatology; 1996; 193(3):177-84. PubMed ID: 8944337
[TBL] [Abstract][Full Text] [Related]
5. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
6. The antiandrogens. When and how they should be used.
Sawaya ME; Hordinsky MK
Dermatol Clin; 1993 Jan; 11(1):65-72. PubMed ID: 8435919
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous hyperandrogenism: role of antiandrogen therapy in acne, hirsutism, and androgenetic alopecia.
Krausz A; Friedman AJ
J Drugs Dermatol; 2013 Nov; 12(11):1297-300. PubMed ID: 24358489
[No Abstract] [Full Text] [Related]
8. 5alpha-reductase isozymes and androgen actions in the prostate.
Zhu YS; Imperato-McGinley JL
Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
[TBL] [Abstract][Full Text] [Related]
9. [Experience in treating androgen-dependent diseases (androgenetic alopecia, acne agminata, hirsutism) with the preparation Diane].
Rubina VV; Korchevaia TA; Kravchenko LIa
Vestn Dermatol Venerol; 1986; (7):21-5. PubMed ID: 2945335
[No Abstract] [Full Text] [Related]
10. Steroid 5alpha-reductase inhibitors in androgen-dependent disorders.
Harris GS; Kozarich JW
Curr Opin Chem Biol; 1997 Aug; 1(2):254-9. PubMed ID: 9667860
[TBL] [Abstract][Full Text] [Related]
11. Acne: effect of hormones on pathogenesis and management.
Shaw JC
Am J Clin Dermatol; 2002; 3(8):571-8. PubMed ID: 12358558
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of 5alpha-reductase inhibitors.
Cilotti A; Danza G; Serio M
J Endocrinol Invest; 2001 Mar; 24(3):199-203. PubMed ID: 11314752
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Buzney E; Sheu J; Buzney C; Reynolds RV
J Am Acad Dermatol; 2014 Nov; 71(5):859.e1-859.e15; quiz 873-4. PubMed ID: 25437978
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
15. [Dermatologic therapy unit anti-androgens].
Nolting S
Fortschr Med; 1977 Mar; 95(12):825-8. PubMed ID: 140141
[TBL] [Abstract][Full Text] [Related]
16. Potential targets in the discovery of new hair growth promoters for androgenic alopecia.
Jain R; De-Eknamkul W
Expert Opin Ther Targets; 2014 Jul; 18(7):787-806. PubMed ID: 24873677
[TBL] [Abstract][Full Text] [Related]
17. [Hormonotherapy in acute, idiopathic hirsutism, and seborrheic alopecia (author's transl)].
Belaube P; Devaux J; Gamby T; Garcin G; Privat Y
Sem Hop; 1982 Jul; 58(26-27):1650-3. PubMed ID: 6287643
[TBL] [Abstract][Full Text] [Related]
18. [Indications and limits of anti-androgen therapy].
Zaun H
Z Hautkr; 1984 Aug; 59(16):1090-7. PubMed ID: 6207673
[TBL] [Abstract][Full Text] [Related]
19. 5 alpha-reductase inhibitors--a new hope in dermatology?
Amichai B; Grunwald MH; Sobel R
Int J Dermatol; 1997 Mar; 36(3):182-4. PubMed ID: 9158996
[No Abstract] [Full Text] [Related]
20. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
